STOCK TITAN

Incyte Genomics (INCY) Stock News, Dec 2022-Mar 2023

INCY NASDAQ

Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.

Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.

Rhea-AI Summary

Incyte announced the discontinuation of the Phase 3 LIMBER-304 trial after an independent data monitoring committee determined it was unlikely to meet its primary endpoint. This trial evaluated the efficacy and safety of parsaclisib combined with ruxolitinib in patients with myelofibrosis who did not respond adequately to ruxolitinib alone. The decision to halt the study was not due to safety concerns. Incyte will review the data and is expected to present findings at a future scientific meeting. The primary endpoint was the reduction in spleen volume, with secondary endpoints including symptom score changes and overall survival.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.20%
Tags
-
Rhea-AI Summary

Incyte announced a positive opinion from the CHMP recommending the approval of ruxolitinib cream (Opzelura) for treating non-segmental vitiligo, marking it as the first treatment for repigmentation available in the EU. With about 1.5 million patients affected in Europe, the recommendation is based on Phase 3 trial data showing significant improvements in facial and total body repigmentation. The European Commission will review the opinion, which, if approved, will provide a critical treatment option for patients aged 12 and older, addressing a significant unmet medical need in dermatology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary

Incyte, a biopharmaceutical company based in Wilmington, Delaware, announced its participation in the Cowen 43rd Annual Health Care Conference. The event is scheduled for March 6, 2023, at 11:10 a.m. (EST) in Boston. The presentation will be available via live webcast on Investor.Incyte.com, with a replay option available for 30 days post-event. Incyte is dedicated to developing proprietary therapeutics addressing serious unmet medical needs. For more details, visit Incyte.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.40%
Tags
conferences
Rhea-AI Summary

Incyte announced positive 52-week results from a Phase 2 study on the oral JAK1 inhibitor povorcitinib for treating hidradenitis suppurativa (HS). The trial demonstrated sustained efficacy, showing significant reductions in abscess and inflammatory nodule counts across all treatment arms. At Week 52, 22-29% of patients achieved complete response (HiSCR100). The open-label extension indicated consistent tolerability, with common adverse events including COVID-19 and acne. The study's findings affirm the potential of povorcitinib as a viable long-term treatment for this debilitating skin condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Summary

Incyte reported a robust financial performance for FY'22, with total net product revenues reaching $2.75 billion, a growth of 18% year-over-year. The company achieved total revenues of $3.4 billion, up 14% YOY. Jakafi net revenues amounted to $2.41 billion, marking a 13% increase, while guidance for 2023 forecasts Jakafi revenues between $2.53 and $2.63 billion. Opzelura Cream also showed significant demand, generating $61 million in Q4'22 alone. The company is optimistic about upcoming clinical trial results and has received a six-month patent extension for Jakafi, now expiring in December 2028. They hold a conference call today at 8:00 a.m. ET to discuss further details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
-
Rhea-AI Summary

Incyte (NASDAQ:INCY) will present at the Guggenheim Healthcare Talks Oncology Day on February 8, 2023, at 1:35 p.m. (EST) in New York. This presentation will be available for live webcast and can be accessed via Investor.Incyte.com. A replay of the event will be available for 30 days after the broadcast.

Based in Wilmington, Delaware, Incyte is a global biopharmaceutical company dedicated to addressing serious unmet medical needs through the development and commercialization of proprietary therapeutics. For more insights, visit Incyte.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences
Rhea-AI Summary

Incyte has announced its fourth quarter and year-end 2022 financial results conference call scheduled for 8:00 a.m. ET on February 7, 2023. Investors can access the press release at 7:00 a.m. ET on the same day. The domestic dial-in number for the call is 877-407-3042 and the international number is 201-389-0864, using conference ID 13735569 for participation. A replay will be available for 30 days, with U.S. replay at 877-660-6853. The live webcast will be accessible at Investor.Incyte.com for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences earnings
-
Rhea-AI Summary

Incyte announced the development of INCA033989, a novel anti-mutant calreticulin monoclonal antibody aimed at treating myelofibrosis (MF) and essential thrombocythemia (ET). This investigational drug was showcased as one of six plenary presentations at the ASH Annual Meeting in December 2022. Clinical trials for INCA033989 are set to commence in 2023. Research highlights Incyte’s capabilities in evaluating new targets for myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
none
-
Rhea-AI Summary

Incyte announced significant findings from its LIMBER trials at the ASH Annual Meeting. Phase 2 data revealed that adding parsaclisib to ruxolitinib (Jakafi®) results in spleen volume reduction and symptom alleviation in patients with myelofibrosis (MF). Additionally, early results from a Phase 1/2 study indicated that INCB00928 safely improves anemia in MF patients. Both studies emphasize the need for alternative therapies for patients unresponsive to current treatments. The company continues to advance its clinical programs with additional Phase 3 trials underway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
none
Rhea-AI Summary

Syndax Pharmaceuticals and Incyte announced promising results from the Phase 1/2 trial of axatilimab in patients with chronic graft-versus-host disease (cGVHD), showing an overall response rate (ORR) of 67% and ORR of 82% at 1 mg/kg every two weeks. The treatment demonstrated broad clinical benefits across multiple organ systems, with a 52% reduction in glucocorticoids for responding patients. Furthermore, axatilimab had a favorable safety profile, with 40% experiencing serious adverse events, yet no high-grade toxicities. Topline data from the AGAVE-201 study is expected mid-2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags

FAQ

What is the current stock price of Incyte Genomics (INCY)?

Incyte Genomics (INCY) last closed at $119.09.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately $24.3B.